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The WNK (with no lysine kinase)–SPAK (SPS1-related
proline/alanine-rich kinase)/OSR1 (oxidative stress-responsive
kinase 1) signalling pathway plays an important role in controlling
mammalian blood pressure by modulating the activity of ion
co-transporters in the kidney. Recent studies have identified
Gordon’s hypertension syndrome patients with mutations in
either CUL3 (Cullin-3) or the BTB protein KLHL3 (Kelch-like
3). CUL3 assembles with BTB proteins to form Cullin–RING E3
ubiquitin ligase complexes. To explore how a CUL3–KLHL3
complex might operate, we immunoprecipitated KLHL3 and
found that it associated strongly with WNK isoforms and CUL3,
but not with other components of the pathway [SPAK/OSR1
or NCC (Na+ /Cl− co-transporter)/NKCC1 (Na+ /K+ /2Cl− co-
transporter 1)]. Strikingly, 13 out of the 15 dominant KLHL3
disease mutations analysed inhibited binding to WNK1 or
CUL3. The recombinant wild-type CUL3–KLHL3 E3 ligase
complex, but not a disease-causing CUL3–KLHL3[R528H]
mutant complex, ubiquitylated WNK1 in vitro. Moreover, siRNA
(small interfering RNA)-mediated knockdown of CUL3 increased
WNK1 protein levels and kinase activity in HeLa cells. We
mapped the KLHL3 interaction site in WNK1 to a non-catalytic
region (residues 479–667). Interestingly, the equivalent region
in WNK4 encompasses residues that are mutated in Gordon’s
syndrome patients. Strikingly, we found that the Gordon’s disease-
causing WNK4[E562K] and WNK4[Q565E] mutations, as well
as the equivalent mutation in the WNK1[479–667] fragment,
abolished the ability to interact with KLHL3. These results
suggest that the CUL3–KLHL3 E3 ligase complex regulates blood
pressure via its ability to interact with and ubiquitylate WNK
isoforms. The findings of the present study also emphasize that
the missense mutations in WNK4 that cause Gordon’s syndrome
strongly inhibit interaction with KLHL3. This could elevate
blood pressure by increasing the expression of WNK4 thereby
stimulating inappropriate salt retention in the kidney by promoting
activation of the NCC/NKCC2 ion co-transporters. The present
study reveals how mutations that disrupt the ability of an E3 ligase
to interact with and ubiquitylate a critical cellular substrate such as
WNK isoforms can trigger a chronic disease such as hypertension.
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INTRODUCTION
Mutations that increase expression of the WNK (with no lysine
kinase) 1 gene result in an inherited hypertension syndrome
termed Gordon’s syndrome or PHAII (pseudohypoaldosteronism
type II) [1]. Missense mutations in the related WNK4 gene that
alter three close-by non-catalytic residues (Glu562, Asp564 and
Gln565) also cause Gordon’s syndrome [1]. How these mutations
influence WNK4 function is unknown. Most evidence points
towards the WNK1 and WNK4 isoforms exerting their effects
on blood pressure through their ability to phosphorylate and
activate two highly related protein kinases termed SPAK [SPS1-
related proline/alanine-rich kinase; also known as STK39 (serine
threonine kinase 39)] and OSR1 (oxidative stress-responsive
kinase 1) [2–4]. SPAK and OSR1 interact with MO25 (mouse
protein-25) isoform subunits to form a maximally activated
complex [5]. The SPAK and OSR1 kinases, once activated
by WNK kinases, phosphorylate and activate members of the
electroneutral cation-coupled chloride co-transporters [SLC12
(solute carrier family 12)], including the NCC (Na+ /Cl− co-
transporter) and NKCC (Na+ /K+ /2Cl− co-transporter) 1 and 2,
that are targets for the blood-pressure-lowering thiazide diuretic
and loop diuretic drugs [4,6–10].
Consistent with the critical role that the WNK1/WNK4-
mediated activation of SPAK and OSR1 plays in regulating blood
pressure, knockin mice expressing a form of SPAK in which the
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NRF2, NF-E2-related factor 2; OSR1, oxidative stress-responsive kinase 1; qRT-PCR, real time quantitative reverse transcription PCR; RBX1, RING-box
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RNA; SPAK, SPS1-related proline/alanine-rich kinase; TAL, thick ascending limb; TTBS, Tris-buffered saline containing Tween 20; UBE1, ubiquitin-like
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T-loop residue is changed to alanine to prevent activation by WNK
isoforms have low blood pressure and reduced phosphorylation
of NCC in the kidney [11,12]. SPAK-knockout mice display a
similar phenotype [13]. Patients with Gordon’s syndrome are also
highly sensitive to thiazide diuretics that target NCC, which is
consistent with the WNK signalling pathway regulating these
critical ion co-transporters [1]. Previous work has revealed that a
significant number of Chinese patients with a low blood pressure
condition, termed Gittleman’s syndrome, possess a mutation of
the major SPAK/OSR1-activating phosphorylation site on NCC
(T60M) [4,14].
Exciting recent research has revealed about 50 unrelated
familial patients with Gordon’s syndrome, possessing no
mutations in the WNK isoforms, but instead displaying mutations
in either CUL3 (Cullin-3) [15] or the BTB-domain containing
protein KLHL3 (Kelch-like 3) [15,16]. CUL3 is the core
scaffolding subunit of a subtype of the largest class of E3 ubiquitin
ligases in the cell, called CRLs (Cullin–RING E3 ligases) [17,18].
Like all ubiquitin E3s, CRLs transfer ubiquitin from an E2 enzyme
on to other proteins, resulting in the formation of ubiquitin chains
linked to the substrate. These chains are recognized by a large
protease called the 26S proteasome, leading to the proteolytic
degradation of the ubiquitin-tagged protein [19]. CUL3 assembles
a multi-subunit modular CRL complex by associating with the
RING-finger protein RBX1 (RING-box 1, E3 ubiquitin protein
ligase) and variable BTB-containing substrate adaptor proteins
[20–22]. The BTB domain directly interacts with the Cullin N-
terminus, whereas the substrate is recruited through other protein-
interaction domains. The best-studied CUL3 substrate adaptor
is the Kelch-like protein KEAP1 (Kelch-like ECH-associated
protein 1), which regulates the proteasomal degradation of the
transcription factor NRF2 {NF-E2-related factor 2; also known
as NFE2L2 [nuclear factor (erythroid-derived 2)-like 2]} [23,24].
Structural studies have revealed that NRF2 directly interacts with
the Kelch-like domain of KEAP1 to position NRF2 for efficient
ubiquitylation by the CUL3–RBX1 core ubiquitin ligase complex
[25,26]. Many other BTB proteins that are known to assemble
with CUL3 also bind their substrates through a Kelch-like domain
[27–29].
The identification of mutations in CUL3 and KLHL3 in
Gordon’s syndrome patients suggests that these two proteins
may also form a CRL E3 complex that regulates blood pressure.
The KLHL3 mutations found are either recessive or dominant,
whereas CUL3 mutations are dominant. Dominant KLHL3
mutations are clustered in short segments within or nearby the
‘Kelch propeller motif’ or the ‘BTB domain’ [15,16], suggesting
that they interfere with either substrate binding or CUL3 binding.
All of the CUL3 mutations identified result in skipping of exon 9,
producing an in-frame fusion of exon 8 and 10 [15,16]. As with
mutations in WNK1 and WNK4, patients with CUL3 and
KLHL3 mutations can be effectively treated with thiazide
diuretics, which inhibit NCC in the distal nephron of the kidney,
suggesting that these mutations activate these ion co-transporters
[15,16]. KLHL3 is reportedly also highly expressed in the distal
convoluted tubule [15,16].
As a first step in exploring the role that a CUL3–KLHL3
complex may play in regulating blood pressure, we searched
for KLHL3-interacting partners. Strikingly, we found that the
wild-type KLHL3 immunoprecipitated from mammalian cell
extracts indeed interacts with CUL3 and also associates with
WNK isoforms, but not other components of the pathway we
have tested. We observed that most of the disease-causing
mutations in KLHL3 or CUL3 investigated impaired binding to
WNK1 or CUL3. We demonstrate that a recombinant wild-type
CUL3–KLHL3, but not a disease-causing non-WNK1-binding
CUL3–KLHL3 complex, robustly ubiquitylates WNK1 in vitro
and that siRNA (small interfering RNA) knockdown of CUL3
increases expression of WNK1. We also present evidence that
the two missense mutations in WNK4 that cause Gordon’s
syndrome abolish its ability to interact with KLHL3. The
results of the present study demonstrate that the CUL3–KLHL3
complex may regulate blood pressure by interacting with and
modulating the ubiquitylation of WNK isoforms. Our findings
highlight that disease-causing mutations that disrupt KLHL3–
WNK interactions lead to Gordon’s syndrome.
MATERIALS AND METHODS
Materials
The materials used were: sequencing-grade trypsin (Promega);
protease-inhibitor cocktail tablets (Roche); Protein G–Sepharose
and all chromatography media (GE Healthcare Lifesciences);
anti-GFP (green fluorescent protein)–agarose beads (Chromotek);
anti-FLAG M2–agarose, Tween 20, Colloidal Blue staining
kit, precast SDS polyacrylamide BisTris gels, LipofectamineTM,
blasticidin and hygromycin (Invitrogen); Nonidet P40 (Fluka);
ampicillin (Merck); bovine ubiquitin and imidazole (Sigma); and
Insect XPRESSTM Media (Lonza).
Plasmids
The full-length coding region of human KLHL3 (GenBank®
accession number NM_017415.2) was amplified by RT
(reverse transcription)–PCR from skeletal muscle total RNA
(Agilent, catalogue number 540029-41) using the primers
5′-GTAGATCTATGGAGGGTGAAAGTGTCAAGCTG-3′ (for-
ward) and 5′-GTGCGGCCGCTCACAAGGACTTGTGAATC-
ACGGC-3′ (reverse). For mammalian expression this was
shuttled into the BamHI/NotI sites of derivatives of pCMV5
and pcDNA5FRT/TO (Invitrogen, catalogue number V6520-
20) vectors containing various N-terminal tags. For baculovirus
expression the wild-type KLHL3 gene was re-amplified to
add a blunt rTEV (recombinant tobacco etch virus) protease
cleavage site to the N-terminus (such that the fusion reads
ENLYFQM where M is the initiating methionine residue
of KLHL3) and subcloned into the BamHI/NotI sites of
a pFBDual vector (Invitrogen, catalogue number 10712-
024) modified to include an N-terminal Dac tag [30]. The
corresponding KLHL3 R528H mutant construct was obtained
by site-directed mutagenesis. Baculovirus co-expression of Dac–
Cullin3 and untagged Rbx1 was achieved by subcloning both
human Cullin3 (GenBank® accession number NM_003590;
synthesized and codon-optimized for insect cell expression by
Genscript) and human Rbx1 [GenBank® accession number
NM_014248; amplified from IMAGE 3138751 with the
primers 5′-GTgctagcATGGCGGCAGCGATGGATGTGGAT-3′
(forward) and 5′-GTggtaccCTAGTGCCCATACTTTTGGAA-
TTC-3′ (reverse), NheI and KpnI sites respectively in lower
case] into the BamHI/NotI and NheI/KpnI sites respectively
of pFBDual-DAC(TEV). All IMAGE clones (I.M.A.G.E.
consortium LLNL) were obtained from Source BioScience U.K.
RT–PCR was performed using Superscript III One Step RT–
PCR (Invitrogen, catalogue number 12574-018) and PCRs using
KOD Hot Start DNA polymerase (Novagen) according to the
manufacturers’ protocols. Point mutations were introduced using
the QuikChange method (Stratagene) in conjunction with KOD
polymerase. (RT–)PCR products were subcloned into StrataClone
PCR vectors (Agilent, catalogue numbers 240207 and 240205)
according to the manufacturer’s instructions and fully sequenced
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prior to further subcloning. DNA sequencing was performed by
The Sequencing Service, College of Life Sciences, University of
Dundee, Dundee, Scotland (http://www.dnaseq.co.uk).
General methods
Restriction enzyme digests, DNA ligations, other recombinant
DNA procedures, electrophoresis, cell culture, transfections,
recombinant protein expression in Escherichia coli or insect cells,
and protein purification were performed using standard protocols.
DNA constructs used for transfection were purified from E. coli
DH5α cells using Qiagen kits according to the manufacturer’s
protocol. All DNA constructs were verified by DNA sequencing,
which was performed by The Sequencing Service using
DYEnamic ET terminator chemistry (GE Healthcare) on
Applied Biosystems automated DNA sequencers. WNK1 activity
was assessed after its immunoprecipitation by measuring by
measuring its ability to phosphorylate kinase-inactive SPAK as
described previously [31].
Antibodies
The antibodies against the following antigens were raised
in sheep and affinity-purified on the appropriate antigen
by the Division of Signal Transduction Therapy Unit at
the University of Dundee: NKCC1 total antibody (residues
1–288 of NKCC1, catalogue number S022D); WNK1
total antibody (residues 2360–2382 of human WNK1,
QNFNISNLQKSISNPPGSNLRTT, catalogue number S062B);
WNK2 total antibody (residues 1605–1871 of human WNK2,
catalogue number S140C); WNK3 total antibody (residues 1142–
1461 of human WNK3, catalogue number S156C); SPAK total
antibody (full-length human SPAK protein, catalogue number
S637B); CUL3 total antibody (residues 554–768 of human CUL3,
catalogue number S067D); KLHL3 total antibody (residues 287–
587 of human KLHL3, catalogue number S377D); anti-GST
(glutathione transferase) antibody (catalogue number S902A);
and anti-GFP antibody (catalogue number S268B). The anti-
FLAG antibody (F1804) was purchased from Sigma–Aldrich and
the anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
and anti-RBX antibodies were purchased from Cell Signaling
Technology. Secondary antibodies coupled to HRP (horseradish
peroxidase) used for immunoblotting were obtained from Pierce.
Buffers
Buffer A contained 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA
and 1 mM DTT (dithiothreitol). The mammalian cells lysis buffer
contained 50 mM Tris/HCl (pH 7.5), 0.15 M NaCl, 1 mM EGTA,
1 mM EDTA, 1 mM Na3VO4, 50 mM NaF, 5 mM Na4P2O7,
0.27 M sucrose, 1% (w/v) Nonidet P40, 1 mM benzamidine,
0.1 mM PMSF, 0.1% 2-mercaptoethanol and Roche protease
inhibitor mix (1 tablet in 50 ml). TTBS (Tris-buffered saline
containing Tween 20) was Tris/HCl (pH 7.5), 0.15 M NaCl and
0.2% Tween 20. SDS sample buffer was 1×NuPAGE LDS
(lithium dodecyl sulfate) sample buffer (Invitrogen), containing
1% (v/v) 2-mercaptoethanol. The bacterial lysis buffer contained
50 mM Tris/HCl (pH 7.5), 0.15 M NaCl, 1 mM EGTA, 1 mM
EDTA, 0.27 M sucrose, 1% (w/v) Triton X-100, 0.1 mM PMSF,
1 mM benzamidine, 0.5 mg/ml lysozome and 0.015 mg/ml DNase
containing 1% (v/v) 2-mercaptoethanol.
Immunoblotting
Samples were heated in sample buffer, subjected to SDS/PAGE
and transferred on to nitrocellulose membranes. Membranes
were blocked for 30 min in TBST, containing 5% (w/v) dried
skimmed milk. The membranes were then incubated overnight
at 4 ◦C in TBST containing 5% (w/v) skimmed milk with the
indicated primary antibody. Sheep antibodies were used at a
concentration of 1–2 μg/ml, whereas commercial antibodies were
diluted 1000–2000-fold. The incubation with phosphospecific
sheep antibodies was performed with the addition of 10 μg/ml
of the dephosphopeptide antigen used to raise the antibody. The
blots were then washed three times with TTBS and incubated
for 1 h at room temperature (25 ◦C) with secondary HRP-
conjugated antibodies diluted 2500-fold in 5% (w/v) skimmed
milk in TTBS. After repeating the washing steps, the signal
was detected with the enhanced chemiluminescence reagent.
Immunoblots were developed using a film automatic processor
(SRX-101, Konica Minolta Medical), and films were scanned
with at 300-d.p.i. resolution on a scanner (V700 PHOTO,
Epson).
Cell culture, stable cell line generation and transfections
HEK (human embryonic kidney)-293 cells were cultured
on 10-cm-diameter dishes in DMEM (Dulbecco’s modified
Eagle’s medium) supplemented with 10% (v/v) foetal bovine
serum, 2 mM L-glutamine, 100 units/ml penicillin and 0.1 mg/ml
streptomycin. HEK-293 T-REx cell lines stably overexpressing
wild-type and mutant forms of KLHL3 and CUL3 were generated
using the Flp-in T-REx system from Invitrogen according to the
manufacturer’s instructions. These human FLAG-tagged wild-
type KLHL3, mutant-KLHL3 stable cell lines and the GFP-
tagged wild-type KLHL3 were selected/cultured in the presence
of 15 μg/ml blasticidin and 0.1 mg/ml hygromycin. Protein
expression was induced for 24 h with 1 μg/ml tetracycline. The
HEK-293 cells stably expressing NCC were described previously
[4]. FLAG-tagged wild-type WNK4 or mutant WNK4 (E562K,
Q565E) stably expressed in HEK-293 cell lines using the Flp-
in T-REx system were used which have generated in our Unit
previously (results not shown). For transient transfection of
WNK1 fragments, or other proteins, LipofectamineTM was used
following the manufacturer’s instructions. Cells were lysed in
0.3 ml of ice-cold lysis buffer per dish. Lysates were clarified
by centrifugation at 26000 g for 15 min and the supernatants
were frozen in aliquots (100 μl) in liquid nitrogen and stored
at − 80 ◦C. Protein concentrations were determined using the
Bradford method. Insect Sf21 cells employed for protein
expression were grown in Insect XPRESSTM Media at a density
of between 1×106 and 6×106 cells/ml.
Immunoprecipitations
For immunoprecipitation of FLAG, GST and GFP, FLAG M2–
agarose beads, glutathione–Sepharose and anti-GFP–agarose
beads were used. For other immunoprecipitations, antibodies were
covalently coupled to Protein G–Sepharose employing dimethyl
pimelimidate [31], at a ratio of 1 μg of antibody per 1 μl of beads.
For immunoprecipitations, 0.2–5 mg of lysates was incubated
with 5–10 μl of antibody–resin conjugate for 1 h at 4 ◦C with
gentle agitation, and the immunoprecipitates were washed three
times with 1 ml of lysis buffer containing 0.5 M NaCl and then
twice with 1 ml of Buffer A. Proteins were eluted by resuspending
the washed immunoprecipitates in 20–100 μl of 1× SDS sample
buffer.
MS analysis
Lysates (5 mg) derived from HEK-293 cells stably expressing
wild-type or mutant FLAG epitope-tagged KLHL3 were subjected
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to immunoprecipitation with anti-FLAG antibody covalently
conjugated to agarose (5 μl). Immunoprecipitates were washed
three times with lysis buffer containing 0.5 M NaCl followed
by two washes with Buffer A. Proteins were eluted from
FLAG beads by resuspending the immunoprecipitates in SDS
sample buffer (30 μl). The immunoprecipitates were subjected
to electrophoresis on a precast 4–12% gradient gel (Invitrogen)
and the protein bands were visualized following Colloidal Blue
staining. Proteins in the selected gel bands were reduced and
alkylated by the addition of 10 mM DTT, followed by 50 mM
iodoacetamide. Identification of proteins was performed by in-
gel digestion of the proteins with 5 μg/ml trypsin and subsequent
analysis of the tryptic peptides by LC (liquid chromatography)–
MS/MS (tandem MS) on a Thermo LTQ-Orbitrap system coupled
to a Thermo Easy nano-LC instrument. Excalibur RAW files were
converted into peak lists by Raw2msm [32] and then analysed by
Mascot (http://www.matrixscience.com), utilizing the SwissProt
human database. Two missed cleavages were permitted, the
significance threshold was P < 0.05.
Proteins for in vitro ubiquitylation reaction
The His–UBE2D3 (ubiquitin-conjugating enzyme E2 D3) E2
conjugating enzyme was expressed in BL21 E. coli cells. His–
UBE1 (ubiquitin-like modifier-activating enzyme 1; E1) was
expressed in insect Sf21 cells. Wild-type KLHL3 or mutant
KLHL3[R528H] were expressed with Dac tags [30] in insect
Sf21 cells. The CUL3-3–Rbx1 complex was expressed from a
multibac vector [33] with a Dac tag on CUL3 and no tag on
Rbx1 in Sf21 cells. The tags on UBE2D3, Cul3–Rbx1 as well
as wild-type or mutant KLHL3[R528H] proteins were cleaved
employing the rTEV protease and the non-tagged proteins were
repurified.
In vitro ubiquitylation assays
For each ubiquitylation assay reaction 5 μl of immunoprecipitated
endogenous WNK1–protein G–Sepharose conjugate derived
from 0.5 mg of HEK-293 cells was used. All other protein
components were expressed and purified as described above.
The ubiquitylation assays contained 20 mM Hepes/HCl (pH 7.5),
150 mM NaCl, 2 mM DTT, 10% (w/v) glycerol, 8 μM Cul3–
Rbx1 complex, 7 μM KLHL3 (wild-type or R528H mutant),
7 μM E1 (UBE1), 60 μM E2 (UBE2D3) and 3000 μM ubiquitin.
Reactions were initiated by adding ATP and MgCl2 to a final
concentration of 1 mM and samples were incubated with agitation
at 30 ◦C for 30 min. Ubiquitylation reactions were terminated by
the addition of SDS sample buffer and samples were analysed
either after separation on a 6% Tris/glycine SDS polyacrylamide
gel followed by immunoblot analysis with anti-WNK1 total
antibody, or following separation on a precast 4–12% gradient
SDS polyacrylamide BisTris gel and immunoblot analysis with
anti-KLHL3 total antibody.
Knockdown experiment of CUL3 in HeLa cells
An siRNA (ON-TARGETplus) oligonucleotide towards human
CUL3 was purchased from Thermo Scientific. The target
sequence probes used were: Probe 1, 5′-GCACAUGAA-
GACUAUAGUA-3′ (catalogue number J-010224-09) and Probe
2, 5′-GAAGGAAUGUUUAGGGAUA-3′ (catalogue number J-
010224-06). For the scrambled control, negative control siRNA
was purchased from Ambion. Transfections were performed as
per the manufacturer’s instructions, using a concentration of
50 nM of siRNA. At 5 days post-transfection, cells were lysed
with lysis buffer, then centrifuged at 26000 g for 15 min and the
supernatants were frozen in aliquots (100 μl) in liquid nitrogen
followed by immunoblotting. Quantitative immunoblotting was
performed using the LI-COR Odyssey imaging system.
qRT-PCR (real-time quantitative RT–PCR)
After transfections of CUL3 siRNA oligonucleotides for 5 days
in 12-well plates, RNA was isolated using a RNeasy micro kit
(Qiagen, catalogue number 74004) and cDNA was made from
1 μg of the isolated RNA using the I-Script cDNA kit (Bio-Rad
Laboratories) according to the manufacturer’s protocol. qRT-PCR
was performed on triplicate samples (10 μl) according to the
manufacturer’s protocol in a CFX 384 Real time System qRT-
PCR machine (Bio-Rad Laboratories). All primers were designed
using PerlPrimer and purchased from Invitrogen. The primers
used were: WNK1 forward, 5′-CAGCAGGTAGAACAATCCAG-
3′ and reverse, 5′-CGTCCCATCAGATAACACAG-3′; GAPDH
forward, 5′-TGCACCACCAACTGCTTAGC-3′ and reverse,
5′-GGCATGGACTGTGGTCATGAG-3′; and RPL13A (ri-
bosomal protein L13a) forward, 5′-CCTGGAGGAGAAGAGGA-
AAGAGA-3′ and reverse, 5′-TTGAGGACCTCTGTGTAT-
TTGTCAA-3′. The primer efficiency was determined and taken
into account when evaluating the qRT-PCR data. The data were
normalized to the geometrical mean of housekeeping genes,
GAPDH and RPL13A. The Pfaffl method was used to analyse
the qRT-PCR data in Microsoft Excel and GraphPad Prism.
RESULTS
Evidence that overexpressed KLHL3 associates with WNK1
To gain insight into how KLHL3 functions, we generated
HEK-293 cells that stably overexpress low levels of wild-
type KLHL3 or two reported dominant KLHL3 mutations
observed in Gordon’s syndrome patients (S432N and
R528H). We immunoprecipitated KLHL3 and analysed the
immunoprecipitations after electrophoresis in a polyacrylamide
gel stained with Colloidal Blue (Figure 1A) and Orbitrap MS
(Figure 1B). This revealed that in the wild-type and mutant
purifications, KLHL3 was indeed the dominant Colloidal Blue-
staining band migrating at the expected molecular mass of
∼65 kDa, and as expected was not observed in the control
immunoprecipitate from HEK-293 cells not overexpressing
KLHL3 (Figure 1A). Consistent with CUL3 representing a key
binding partner for KLHL3 we observed that CUL3 migrating
with a molecular mass of ∼90 kDa was co-immunoprecipitated
with the wild-type KLHL3 (Figures 1A and 1B), indicating that
KLHL3 can form a CRL complex with CUL3. Interestingly,
the two selected mutant KLHL3[S432N] and KLHL3[R528H]
proteins associated with CUL3 at a similar extent as the wild-
type KLHL3, indicating that these mutations do not disrupt
the ability to interact with CUL3. The most striking feature
of the KLHL3 immunoprecipitations was an intensely Colloidal
Blue-staining band migrating at >250 kDa observed with wild-
type KLHL3 whose intensity was markedly reduced in the
KLHL3[R528H] mutant and was absent from the KLHL3[S432N]
mutant (Figure 1A). This band was also absent from the control
immunoprecipitate undertaken from non-KLHL3-overexpressing
HEK-293 cells. Strikingly, MS analysis revealed that this region
of the gel derived from wild-type KLHL3 immunoprecipitate
contained significant levels of WNK1, WNK2 and WNK3
isoforms emphasized by very high Mascot scores (WNK1-3228,
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Figure 1 Evidence that KLHL3 associates with WNK isoforms and interaction is impaired by Gordon’s syndrome mutations
(A) Control HEK-293 cells or HEK-293 cells stably expressing the indicated forms of wild-type and mutant KLHL3 possessing an N-terminal FLAG tag were cultured in the presence of 1 μg/ml tetracyclin
to induce expression of KLHL3. Cells were lysed and KLHL3 was immunoprecipitated from 5 mg of extract using an anti-FLAG antibody covalently coupled to agarose. The immunoprecipitates were
electrophoresed on an SDS polyacrylamide gel and protein bands visualized following Colloidal Blue staining. Molecular masses are shown on the left-hand side in kDa. (B) The labelled Colloidal
Blue-stained bands identified in (A) were excised from the gel and digested with trypsin, and their identities were determined by tryptic peptide mass-spectral fingerprinting, as described in the
Materials and methods section. Accession numbers are for the NCBI Entrez Protein database. Mascot protein scores >67 were considered significant (P < 0.05). N.P.D., no significant protein identity
determined. MW, molecular mass. (C) As (A), except that the immunoprecipitates were immunoblotted with the indicated antibodies. Similar results were obtained in three separate experiments.
Molecular masses are shown on the left-hand side in kDa.
WNK2-842 and WNK3-463; Figure 1B). WNK1 was also
detected within the KLHL3[R528H] mutant immunoprecipitate,
but consistent with the reduced intensity of the >250 kDa band
observed by Colloidal Blue staining, the Mascot scores for WNK1
was markedly lower (455) than observed for the wild-type KLHL3
(Figure 1B). No WNK2 or WNK3 was detected associated with
the KLHL3[R528H] mutant (Figure 1B). In accordance with the
absence of the >250 kDa Colloidal Blue-staining band in
the KLHL3[S432N] immunoprecipitate, no detectable presence
of any WNK isoforms was revealed by MS analysis of these
samples.
Immunoblot analysis of KLHL3 immunoprecipitates confirmed
observations made by MS that association of the KLHL3[R528H]
mutant with WNK1 were significantly reduced compared with the
wild-type KLHL3 and that KLHL3[S432N] failed to interact with
WNK1 (Figure 1C). This analysis also established that mutant
KLHL3[S432N] or KLHL3[R528H] interacted similarly with
CUL3 to the wild-type KLHL3.
Dominant disease-causing KLHL3 mutations interfere with either
association to WNK1 or CUL3
We next selected 15 different dominant Gordon’s syndrome
mutations located in different domains of KLHL3 (Figure 2A),
generated in stable HEK-293 cell lines, and tested how each
mutation affects association with CUL3 and WNK1 (Figure 2B).
This strikingly revealed that 13 of the mutations tested either
inhibited binding to CUL3 or WNK1, whereas two mutations
(A340V and A494T) did not markedly impair association with
either protein (Figure 2B). Mutations that impaired binding
to CUL3 were located within either the BTB domain (A77E,
M78V and E85A) or the adjacent BACK domain (C164F) found
in other BTB-containing Kelch proteins which have also been
implicated in mediating binding to CUL3 [34]. Interestingly,
mutations within the BACK domain of another Kelch-like adaptor
protein, KLHL7 (Kelch-like family member 7), cause autosomal-
dominant retinitis pigmentosa [35]. Mutations that inhibited
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Figure 2 Evidence that dominant KLHL3 Gordon’s syndrome mutations impair binding to CUL3 or WNK
(A) Schematic representation of the domain structure of KLHL3 with the positions of the dominant Gordon’s syndrome-associated mutations illustrated. The amino acid boundaries of the domains are
indicated. PHAII, pseudohypoaldosteronism type II. (B) Control HEK-293 cells or HEK-293 cells stably expressing the indicated forms of wild-type (WT) and mutant KLHL3 possessing an N-terminal
FLAG tag were cultured in the presence of 1 μg/ml tetracyclin to induce expression of KLHL3. Cells were lysed and KLHL3 was immunoprecipitated (IP) from 0.2 mg of extract using an anti-FLAG
antibody covalently coupled to agarose. The immunoprecipitates (upper panel) as well as whole-cell extracts (lysates, lower panel) were immunoblotted with the indicated antibodies. All gels were
immunoblotted in parallel. The broken lines indicate that samples were run on separate gels. Similar results were obtained in three separate experiments. Molecular masses are shown on the left-hand side
in kDa.
KLHL3 binding to WNK1 (Q309R, R384Q, L387P, S410L,
S432N, R528H, R528C and N529K) were located in the predicted
substrate-binding KLHL repeat motifs.
Evidence that KLHL3 interacts with WNK1, but not with SPAK/OSR1
or NKCC1/NCC
To investigate whether KLHL3 might interact with other known
components of the WNK signalling pathway we transiently
overexpressed wild-type KLHL3 or three disease-causing KLHL3
mutants in HEK-293 cells. We then immunoprecipitated
WNK pathway components (WNK1, SPAK/OSR1, NKCC1
and NCC) and tested whether we could detect association of
these with KLHL3 by immunoblot analysis. This confirmed
association between WNK1 and the wild-type KLHL3, but
no detectable co-immunoprecipitation was observed with
SPAK/OSR1 (immunoprecipitated with an antibody that
recognizes both kinases) or NKCC1 (Figure 3A). We also
overexpressed KLHL3 in HEK-293 cells that stably overexpress
the NCC ion co-transporter and failed to detect association
of KLHL3 with NCC under conditions where interaction with
WNK1 was readily observed (Figure 3B).
WNK1 is a substrate for the CUL3–KLHL3 complex in vitro
To investigate the ability of the CUL3–KLHL3 complex to
directly ubiquitylate WNK1, we expressed and purified the
CUL3–RBX1 core complex, as well as the wild-type KLHL3
and mutant KLHL3[R528H] (Figure 4A). Wild-type KLHL3 and
CUL3–RBX1 were mixed and used in in vitro ubiquitylation
reactions that also contained ubiquitin E1, ubiquitin E2 (UBE2D3)
and ubiquitin. When immunoprecipitated WNK1 was added to
the reaction in the presence of magnesium and ATP, we observed
extensive ubiquitylation of WNK1 (Figure 4B). Moreover, we
observed no WNK1 ubiquitylation when the WNK1-binding
mutant form of KLHL3[R528H] was used in the assay in place
of the wild-type protein (Figure 4C). WNK1 ubiquitylation
was not detected in the absence of either CUL3 or KLHL3
or any of the proteins that function upstream of the CRL in
the ubiquitylation cascade (E1, E2D and ubiquitin; Figure 4B).
These results demonstrate that CUL3–KLHL3 forms an active
CRL complex that through the binding of KLHL3 to WNK1
can target WNK1 for ubiquitylation. We furthermore detected
CUL3–RBX1-dependent ubiquitylation of KLHL3 in the in vitro
ubiquitylation reactions, indicating that CUL3–RBX1 could
directly regulate KLHL3 (Figure 4D). This reaction was more
pronounced in the presence of WNK1 and further work is required
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Figure 3 Evidence that wild-type or dominant KLHL3 Gordon’s syndrome mutations do not interact with SPAK/OSR1 or NKCC1 or NCC
(A) HEK-293 stably expressing the wild-type (WT) and indicated mutants of KLHL3 possessing an N-terminal FLAG epitope were cultured in the presence of 1 μg/ml tetracyclin to induce the
expression of KLHL3. WNK1, SPAK/OSR1 and NKCC1 were separately immunoprecipitated (IP) from 0.2 mg of extract using previously characterized immunoprecipitating antibodies covalently
coupled to Protein G–Sepharose. Whole-cell extracts (lysates, upper panel) as well as immunoprecipitates (lower panels) were immunoblotted with the indicated antibodies. (B) N-terminal GFP-tagged
wild-type KLHL3 was transiently transfected into previously characterized HEK-293 cells stably expressing FLAG–NCC [4]. At 24 h post-transfection cells were cultured for a further 24 h with 1 μg/ml
tetracyclin to induce NCC expression before lysis. GFP–KLHL3 was immunoprecipitated from 0.2 mg of extract employing anti-GFP antibody covalently coupled to agarose. Whole-cell extracts
(lysates, left-hand panel) as well as immunoprecipitates (right-hand panel) were immunoblotted with the indicated antibodies. Similar results were obtained in three separate experiments. Molecular
masses are shown on the left-hand side in kDa.
to establish whether binding of WNK1 to the KLHL3 – CUL3
complex stimulated CRL complex activity resulting in increased
ubiquitylation of KLHL3.
siRNA knockdown of CUL3 increases WNK1 expression and activity
in HeLa cells
We next attempted to reduce CUL3 or KLHL3 expression
employing an siRNA approach to establish the impact this had
on WNK1 expression and activity. Although we were unable to
reduce KLHL3 expression robustly with any siRNA tested (results
not shown), we could reduce CUL3 expression over 4-fold by
employing two different siRNA oligonucleotides purchased from
Thermo Scientific (Figure 5 and Supplementary Figure S1 at
http://www.biochemj.org/bj/451/bj4510111add.htm). Consistent
with the CUL3-dependent ubiquitylation of KLHL3 we observed
in vitro (Figure 4D), the knockdown of CUL3 was associated
with a marked increase in the expression levels of KLHL3
(Figure 5C and Supplementary Figure S1), further suggesting
that CUL3 directly regulates the levels of KLHL3. We
also observed that CUL3 knockdown consistently increased
endogenous WNK1 expression approximately 2-fold (Figures 5A
and 5D, and Supplementary Figure S1). Using qRT-PCR we
studied the relative mRNA expression of WNK1 and found
that CUL3 knockdown did not impact on WNK1 mRNA levels
(Figure 5E), suggesting that the up-regulation of WNK1 under
these conditions is not triggered by an elevation of gene
expression. We also measured endogenous WNK1 activity after
its immunoprecipitation assessed by its ability to phosphorylate
kinase-inactive SPAK expressed in E. coli cells [31]. This revealed
that CUL3 knockdown was accompanied by a ∼1.6-fold increase
in WNK1 activity (Figure 5F).
Evidence that Gordon’s syndrome WNK4 missense mutations
inhibit binding to KLHL3
To map the region on WNK1 that mediates binding to KLHL3
we expressed various fragments of GST-tagged WNK1 in HEK-
293 cells stably expressing the wild-type GFP–KLHL3 and
tested which WNK1 fragments interacted. This revealed that
the smallest fragment of WNK1 tested that interacted with
KLHL3 encompassed residues 479–667, a non-catalytic region
immediately C-terminal to the kinase domain that possesses
a coiled-coiled domain (Figures 6A and 6B). Interestingly,
the equivalent region in WNK4 encompasses residues Glu562,
Asp564 and Gln565 located near to the coiled-coiled domain that
are mutated in patients with Gordon’s hypertension syndrome
(Figure 6A). Transgenic and knockin mice expressing these
WNK4 mutations display marked hypertension [36,37], but
the molecular mechanism by which these mutations disrupt
WNK4 function to cause hypertension is unclear. To test
whether WNK4 missense mutations affected interactions with
KLHL3 we expressed GFP–KLHL3 in HEK-293 cells stably
expressing similar levels of the wild-type WNK4 as well as
two reported disease-causing mutations (WNK4[E562K] and
WNK4[Q565E]). Immunoprecipitation studies confirmed that
the wild-type WNK4 robustly bound to KLHL3, but interaction
with either disease-causing WNK4 mutant tested was strikingly
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Figure 4 WNK1 is a substrate for the CUL3–KLHL3 complex in vitro
(A) Coomassie Blue-stained SDS/PAGE gel of Cul3–Rbx1–KLHL3 wild-type, Cul3–Rbx1–KHLH3[R528H], ubiquitin (Ub), E1 and UBE2D3 used in the in vitro reactions in which all tags used for
affinity purification of each protein has been removed with the rTEV protease and the proteins were re-purified. The line indicates that samples were run on separate gels. (B) Immunoprecipitated
WNK1 from HEK-293 cells was incubated at 30◦C for 30 min with purified E1, E2 (UBE2D3), Cullin3–Rbx1, KLHL3 and ubiquitin in the presence of 1 mM ATP. Control reactions were performed
whereby one of the proteins required for ubiquitylation was omitted from the reaction as indicated. Samples were subjected to immunoblot (IB) analysis with an anti-WNK1 antibody. (C) Ubiquitylation
reactions were performed as in (B) and the ability of KLHL3 R528H to promote WNK1 ubiquitylation was analysed. Independent duplicate reactions are shown. (D) Ubiquitylation reactions were
performed as in (B) and the ubiquitylation of KLHL3 was analysed by immunoblot detection with anti-KLHL3 total antibody. Similar results were obtained in three separate experiments. Molecular
masses are shown on the left-hand side in kDa.
impaired (Figure 6C). As the residues whose mutation in WNK4
causes Gordon’s syndrome are conserved in WNK1 (Figure 6A),
we generated the equivalent disease-causing mutations in the
KLHL3-binding WNK1[479–667] fragment and observed that
all mutations (E633K, D635A and Q636E) ablated binding to
KLHL3 (Figure 6D).
DISCUSSION
The identification of mutations in CUL3 and KLHL3 that cause
Gordon’s syndrome suggested that this CUL3–KLHL3 ubiquitin
ligase complex plays a critical role in regulating blood pressure.
We have now demonstrated that CUL3 and KLHL3 indeed interact
to form a functional CRL E3 complex. Importantly, we found that
in addition to CUL3, KLHL3 also interacts with the WNK1 and
WNK4 isoforms mutated in patients with Gordon’s syndrome
[1]. Moreover, many of the identified Gordon’s disease-causing
mutations (Q309R, R384Q, L387P, S410L, S432N, R528H,
R528C and N529K) located within the putative substrate-binding
Kelch-like domain of KLHL3 markedly interfere with binding to
WNK1. These data, together with the fact that we were able
to successfully reconstitute the KLHL3-dependent ubiquitylation
of WNK1 in vitro and to increase WNK1 expression following
CUL3 knockdown in vivo, suggest that WNK1 is a substrate
for CUL3–KLHL3 and therefore defines a new substrate
adaptor/substrate module for a CUL3 complex implicated in
human disease.
The results of the present study furthermore suggest that
WNK1 is the critical substrate for CUL3–KLHL3 in the control
of blood pressure, as 8 out of 15 mutations that we have
tested disrupt the interaction of KLHL3 with WNK1. We have
identified five other mutations that interfere with binding to CUL3,
which would also be expected to impair the ability of CUL3
to regulate ubiquitylation of WNK1. As expected from these
results, a disease-causing mutation of KLHL3 that no longer
binds to WNK1 also abolished WNK1 ubiquitylation in vitro.
As hyperactive WNK1 is known to cause high blood pressure, the
control of WNK1 protein abundance by ubiquitylation through
CUL3–KLHL3 may be critical for blood pressure control. Thus
we propose that a lack, or reduction, of WNK1 ubiquitylation
in patients carrying mutations in CUL3 or KLHL3 may result in
the observed hypertensive phenotype. Further work is required to
investigate this hypothesis.
Given that it is the role of the WNK signalling pathway
in the key DCT (distal convoluted tubule) and TAL (thick
ascending limb) of the kidney that controls blood pressure,
it is possible that regulation of WNK isoforms by the
CUL3–KLHL3 occurs mainly in these highly specialized cells
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Figure 5 Evidence that CUL3 knockdown enhances WNK1 expression and activity
HeLa cells were treated with 50 nM scrambled siRNA or CUL3-directed siRNA (probe 1) for 5 days and cells were lysed. (A) Cell lysates were subjected to immunoblotting with the indicated antibody.
Each lane contains cell extract from an independent dish of cells from an identical experiment undertaken on the same day. (B–D) Quantitative LI-COR immunoblot analysis was undertaken and the
ratio of CUL3 (B), KLHL3 (C) and WNK1 (D) to GAPDH was quantified. Results are means+−S.E.M. for two independent samples each assayed in duplicates with P values indicated. (E) Total mRNA
was isolated from cells and WNK1 mRNA levels were determined by qRT-PCR. Data were normalized to internal GAPDH and RPL13A controls as described in the Materials and methods section.
Results are means+−S.D. for three independent samples each assayed in triplicate. (F) WNK1 was immunoprecipitated from 0.25 mg of cell extracts and assayed for its ability to phosphorylate kinase
inactive SPAK expressed in E. coli cells. The top panel displays activity in 32P radioactivity incorporated into kinase inactive SPAK (c.p.m.) as mean+−S.D. The lower panels display representative
immunoblot analysis of WNK1, autorad of phosphorylated SPAK and Coomassie Blue staining of kinase-inactive SPAK employed in the kinase assay. Similar findings were made with an independent
CUL3-directed siRNA (probe 2); see data in Supplementary Figure S1 (at http://www.biochemj.org/bj/451/bj4510111add.htm). Cont, control; KD, kinase-dead; IP, immunoprecipitation; RNAi, RNA
interference.
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Figure 6 Evidence that WNK4 Gordon’s syndrome missense mutations impair binding to KLHL3
(A) Schematic diagram of WNK1 and WNK4 isoform structures and the relative placement of their kinase domain, auto-inhibitory domain (AID) and predicted coiled-coiled domains (CCD). Also high-
lighted in WNK4 is the location of the E562K and Q565E mutations found in Gordon’s hypertension patients. CCD, coiled-coil; CT, C-terminal. (B) HEK-293 cells stably expressing GFP–KLHL3 were
transfected with GST-tagged constructs encoding the indicated fragments of WNK1. At 24 h post-transfection the cells were treated with tetracyclin (1 μg/ml) to induce KLHL3 expression and cells were
lysed after a further 24 h. Cell extracts were subjected to affinity purification on glutathione–Sepharose and immunoblotted with an anti-GFP antibody (top panel) or subjected to affinity purification with an
anti-GFP antibody and immunoblotted with an anti-GST antibody (upper middle panel). Cell lysates were also subjected to immunoblot analysis with an anti-GST (lower middle panel) or anti-GFP (bottom
panel) antibody. Similar results were obtained in two independent experiments. (C) HEK-293 cells stably expressing the wild-type (WT) and indicated mutant forms of FLAG-tagged WNK4 were
transfected with wild-type GFP-tagged KLHL3. At 24 h post-transfection cells were treated with tetracyclin (1 μg/ml) to induce WNK4 expression and cells were lysed after 24 h. Extracts were subjected
to affinity purification using an anti-FLAG antibody (to immunoprecipitate WNK4; upper panels) or an anti-GFP antibody (to immunoprecipitate KLHL3; lower panels) and immunoblotted with the indi-
cated antibodies. Cell lysates were also immunoblotted with the indicated antibodies. Similar results were obtained in two independent experiments. (D) As (B) except that the wild-type and indicated
mutants of the WNK1[479–667] fragment were analysed for their ability to interact with KLHL3. IP, immunoprecipitation. Molecular masses are shown on the left-hand side of the gels in kDa.
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geared to regulate salt reabsorption. This might explain why
siRNA knockdown of CUL3 in HeLa cells only moderately
affected WNK1 expression and possibly more striking effects
would be observed in DCT or TAL cells expressing mutated
CUL3–KLHL3. Relating to this point it is worth stressing
that even a moderate, less than 2-fold, effect on WNK
isoform expression in DCT/TAL kidney cells could still have
a sufficient impact on WNK signalling to stimulate NCC/NKCC2
inappropriately and induce hypertension. It is likely that further
analysis of this system will need to await the availability of
Gordon’s disease knockin mutations in KLHL3 whose design
will be facilitated by the results of the present study. It will
be fascinating to establish how mutations that impair KLHL3
binding to WNK isoforms have an impact on WNK isoform
protein expression, ubiquitylation and activity and how this affects
NCC/NKCC2 ion co-transporters and hence blood pressure.
How missense mutation of three close-by non-catalytic
residues on WNK4, namely Glu562, Asp564 and Gln565, which
lie immediately after the coiled-coiled domain, lead to Gordon’s
hypertension syndrome was unknown. In previous work we have
not observed any significant change in the intrinsic kinase specific
activity of any of the WNK4 disease-causing mutants that we have
tested (D. R. Alessi, unpublished work). The finding that disease-
causing mutations of Glu562 and Gln565 markedly impair binding
to KLHL3 is very exciting, as this suggests that loss of interaction
with CUL3–KLHL3 may lie at the heart of understanding how
missense mutations in these residues of WNK4 results in Gordon’s
syndrome. Interestingly, we have also found that mutating the
highly conserved equivalent residues in WNK1 ablates interaction
with KLHL3 (Figure 6D). These findings suggest that this region
of WNK1 and WNK4 may operate as the major recognition
site for the KLHL3–CUL3 complex. In future work it will be
important to study levels of WNK4 protein in patient-derived cells
(DCT and TAL if feasible) with missense WNK4 mutations of
Glu562, Asp564 and Gln565. It would be critical to establish whether
WNK4 mutations enhanced the levels of WNK4 protein and
how mutations affected the ubiquitylation of WNK4. Although
WNK4[D564A] knockin mice that develop hypertension have
been described, unfortunately no direct quantitative comparison
of the relative expression levels of the wild-type and mutant
WNK4 in any tissue was presented in that study [37]. This will
be essential to undertake in future work.
It will also be interesting to investigate whether WNK1
ubiquitylation by CUL3–KLHL3 occurs constitutively or in
response to a given environmental stimulus. It will be interesting to
establish whether binding of KLHL3–CUL3 to the WNK isoforms
activates E3 ligase activity. An important question to answer is
also whether ubiquitylation of WNK targets it for proteasomal
degradation and/or is involved in regulating WNK activity in
some other manner. The fact that levels of WNK1 increase after
CUL3 knockdown suggests that proteasomal degradation may
play some part in WNK regulation. The transcription factor NRF2,
the best-studied substrate of CUL3, is constitutively ubiquitylated
and targeted for degradation by the ubiquitin–proteasome system
and is only stabilized when the cell encounters oxidative stress,
which allows it to initiate its protective transcriptional programme
[38]. One could similarly imagine a situation where WNK1 is
a constitutive substrate of CUL3–KLHL3 and ubiquitylation is
only halted upon a hypotonic stimulus to allow salt retention in
the kidney. However, the degradation of other CRL substrates is
not constitutive, but rather initiated by a signal, which usually
results in post-translational modification of the substrate allowing
it to be recognized by the CRL [18]. Which of these two
possibilities pertains to WNK1 ubiquitylation remains to be
determined.
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Figure S1 Further evidence that CUL3 knockdown enhances WNK1 expression and activity
HeLa cells were treated with 50 nM scrambled siRNA or CUL3-directed siRNA (probe 2) for 5 days and the cells were lysed. (A) Cell lysates were subjected to immunoblotting with the indicated
antibody. Each lane contains cell extract from an independent experiment. Molecular masses are shown on the left-hand side in kDa. (B–D) Quantitative LICOR immunoblot analysis was undertaken
and the ratio of CUL3 (B), KLHL3 (C) and WNK1 (D) to GAPDH was quantified. Results are means+−S.D. Cont, control; IP, immunoprecipitation; KD, kinase-dead; RNAi, RNA interference.
Received 20 December 2012/4 February 2013; accepted 6 February 2013
Published as BJ Immediate Publication 6 February 2013, doi:10.1042/BJ20121903
c© The Authors Journal compilation c© 2013 Biochemical Society
